tbuckley/cabot-search huggingface dataset:
P83 Intravenous drug use: not a barrier to achieving a sustained virological
Authors: J Dillon, H Jafferbhoy, M Miller, J Tait, S Cleary
Journal: Gut (2010)

Introduction  Chronic hepatitis C (CHC) is a leading cause of liver disease with a variable rate of progression to decompensated cirrhosis, hepatocellular carcinoma and death. It is a common infection among intravenous drug users (IDU). It can be cured by combination therapy of Pegylated interferon and Ribavarin. IDU patients are under represented in many treatment cohorts, this has been justified on grounds of safety and the fear that lowered treatment success would reduce the cost effectiveness of therapy.  Aim  To ascertain in routine clinical practice the outcomes of treating individuals with HCV who are active IDU or are on substitution therapy such as methadone. The primary outcome measure was the rate of sustained virological response (SVR) in those from an IDU background compared to those infected by other aetiologies.  Method  The HCV treatment database was retrospectively analysed for consecutively treated patients. The patients treated were divided in three groups based on the risk category for acquisition of Hepatitis C. Primary end point was SVR which was calculated on intention to treat basis in these groups. Similarly patients were not excluded because of co-infection with HBV and HIV or comorbidity such as haemophilia and chronic renal failure.  Results  We assessed treatment outcome in 291 consecutively treated, predominately treatment naive patients who received Peg interferon and Ribavarin for HCV. They were predominately male (70.3%) in the economically productive age group with 10% of the patients having cirrhosis. Major genotype was three accounting for 53.9% followed by G1 at 36.7%. The overall SVR rate was 55.3%. The SVR rates achieved were; Non IDU 61.4%, Ex IDU 54.8%, and Active IDU 47.1% (p=n/s). In each of the three groups G1 patients obtained an SVR of ; Non IDU 52.7%, Ex IDU 30.7% and active IDU 35.4% (p=n/s). In the non G1 patients non IDU 65.1%, Ex IDU 76.7% and active IDU 53.5%. Ex IDU had a significantly better SVR than active IDU (p=0.02), other differences not significant.  Conclusion  Our results demonstrate that with simple support SVR rates in the active drug user group can be achieved which are comparable with non IDU infected individuals. Intravenous drug use should not be seen as a barrier to treatment of individuals with HCV.
Head of NHS calls for extra money for mental health services
Authors: Adrian O’Dowd
Journal: BMJ (2016)

The head of the NHS in England has told MPs that more money is needed to help speed up improvements in mental health services.

Simon Stevens, chief executive of NHS England, made the comments on 15 June during an evidence session of the parliamentary Public Accounts Committee for its inquiry into improving access to mental health services. The catalyst for the inquiry was a report on preparations for improving access to mental health services published in April.1 The report, by the public spending watchdog the National Audit Office, said that although progress had been made “much remains to be …
Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC).
Authors: Howard Kaufman, Thomas Amatruda, John J. Nemunaitis, Jason Alan Chesney, Keith A. Delman, Lynn E. Spitler, Frances A. Collichio, Merrick I. Ross, Yang Zhang, Mark Shilkrut, Robert Hans Ingemar Andtbacka
Journal: Journal of Clinical Oncology (2015)

9074 Background: T-VEC is an HSV-1 derived oncolytic immunotherapy designed to selectively replicate in tumors, produce GM-CSF, and enhance systemic antitumor immune responses. We describe factors associated with clinical outcomes in 436 pts with previously treated or untreated, unresected stage IIIB-IV MEL in OPTiM, a randomized (2:1) phase 3 trial of intralesional T-VEC vs subcutaneous GM-CSF. Methods: Multivariate analyses (MVAs) and Cox regression were used to evaluate association of BTB (sum of products of 2 largest perpendicular diameters [per investigator] of measurable lesions at baseline), stage (IIIB/C/IVM1a vs IVM1b/c), treatment (tx) line (TL; 1st vs ≥ 2nd), and ECOG PS (0 vs 1), previously reported to be associated with clinical outcomes, with overall response rate (ORR), durable response rate (DRR; continuous PR or CR ≥ 6 months), and overall survival (OS). Results: 288 T-VEC and 126 GM-CSF pts had available BTB; all received tx as randomized. Median BTB: 14.8 cm2 (interquartile range, 5.8-39.3) for T-VEC, 14.1 cm2 (5.7-31.0) for GM-CSF (P = 0.50). Median BTB was higher with advanced stage (IVM1b/c: 23.6 [11.5-53.1]; IIIB/C/IVM1a: 8.6 [3.2-23.2], P < 0.001) and later TLs (≥ 2nd: 18.0 [7.0-45.9]; 1st: 12.9 [5.3-25.6], P < 0.001). In MVA of T-VEC pts (Table), BTB < median, stages IIIB/C/IVM1a, and 1st TL were associated with improved ORR and DRR; BTB < median and stages IIIB/C/IVM1a were associated with better OS. In MVA of all OPTiM pts, T-VEC tx (vs GM-CSF; HR 0.74, 95% CI 0.58-0.96, P = 0.023), BTB < median (HR 0.42, 95% CI 0.32-0.54, P < 0.001), stages IIIB/C/IVM1a (HR 0.54, 95% CI 0.42-0.69, P < 0.001), and ECOG 0 (HR 0.63, 95% CI 0.49-0.82, P < 0.001) were associated with better OS. Conclusions: Based on these exploratory analyses, BTB was prognostic for OS and achieving a DR and OR with T-VEC in OPTiM. BTB should be further evaluated as a prognostic factor in future MEL trials. ORR DRR OS OR (95% CI) P OR (95% CI) P HR (95% CI) P BTB < median vs ≥ median 4.51 (2.47, 8.23) < 0.001 4.40 (2.11, 9.17) < 0.001 0.33 (0.24, 0.45) < 0.001 IIIB/C/IVM1a vs IVM1b/c 3.71 (1.96, 7.01) < 0.001 2.97 (1.38, 6.43) 0.006 0.49 (0.36, 0.68) < 0.001 TL 1st vs ≥ 2nd 2.41 (1.35, 4.28) 0.003 2.38 (1.23, 4.60) 0.01 0.75 (0.55, 1.01) 0.06 OR: odds ratio.
Effect of Added Phosphate on Glutamine Desamidation in Tumors
Authors: Jesse P. Greenstein, Florence M. Leuthardt
Journal: JNCI Journal of the National Cancer Institute (1948)

Effect of Added Phosphate on Glutamine Desamidation in Tumors Get access Jesse P. Greenstein, Jesse P. Greenstein chief biochemist Search for other works by this author on: Oxford Academic PubMed Google Scholar Florence M. Leuthardt Florence M. Leuthardt assistant biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 8, Issue 4, February 1948, Pages 161–162, https://doi.org/10.1093/jnci/8.4.161 Published: 01 February 1948 Article history Received: 22 December 1947 Published: 01 February 1948
Soluble LR11, GCSF−induced Migration Regulator from Myeloid Cells, Is Highly Increased in Chronic Myeloid Leukemia
Authors: Naomi Shimizu, Hideaki Bujo, Meizi Jiang, Keigo Nishii, Emiko Sakaida, Chikako Ohwada, Masahiro Takeuchi, Naoya Mimura, Yusuke Takeda, Shokichi Tsukamoto, Tomoya Muto, Ichiro Tatsuno, Chiaki Nakaseko
Journal: Blood (2014)
QOS-34CHOC CHILDREN'S<i>FIT BRAIN</i>: A CASE STUDY OF AN INNOVATIVE COGNITIVE REMEDIATION PROGRAM FOR PEDIATRIC CANCER SURVIVORS
Authors: Lara C. K. Tucci, Gabriella M. Santacruz, Beverly Shieh, Grace Mucci, Chris Min, Violet Shen
Journal: Neuro-Oncology (2016)
Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia
Authors: O M Wolkowitz, D Pickar, A R Doran, A Breier, J Tarell, S M Paul
Journal: American Journal of Psychiatry (1986)

Alprazolam, when added under double-blind conditions to a stable neuroleptic regimen in two patients with schizophrenia, resulted in clinically apparent improvement in positive and negative schizophrenic symptoms. Both patients showed significant worsening of symptoms following reduction or discontinuation of alprazolam.
Black Hole in the Breast
Authors: Prasad Guntur Ramkumar, Brooke Lawson, Ewan Eadie, John Davidson
Journal: Clinical Nuclear Medicine (2015)

We report an unusual artifact, which was seen on a routine preoperative chest radiograph performed in a patient with breast cancer, before an elective mastectomy. Subsequently, this was identified to be secondary to a preoperative sentinel node injection. The report discusses the diagnostic dilemma caused by this artifact and raises the awareness of this possibility in patients undergoing these commonly performed procedures and investigations.
SMOKING IN PULMONARY TUBERCULOSIS
Authors: M WINKELMANN
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hippocrates, Healing, and Healthcare Materials
Authors: Jose Oliveira, Lorna Stimson
Journal: Advanced Healthcare Materials (2013)

Hippocrates, father of modern medicine, said that healing is not just a matter of time, but sometimes also a matter of opportunity.In recent years, advances in biomedical materials science have provided ever more opportunity for healing, from improved diagnostics through to effective treatment, offering a more comfortable standard of living and increased live expectancy for patients suffering from disease, illness, or injury.
Complete Triplication of the Ureter
Authors: R W Weinberg
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Case 21-1975
Authors: Henning Pontoppidan, Eugene J. Mark
Journal: New England Journal of Medicine (1975)

Presentation of CaseA 20-year-old woman was admitted to the hospital because of pneumonia.She was in excellent health until one week previously, when she awoke with a headache and a mild sore throat. In the evening a hacking, nonproductive cough developed. On the next day headache recurred, with anorexia and feverishness, followed by chills, sweats and diffuse muscular aches. Five days before entry dyspnea at rest developed, with repeated sweats and rise of the temperature to 39.9° C. She went to another hospital, where an x-ray film was reported to disclose pneumonia. Ampicillin was given, but the symptoms persisted. . . .
Changing patterns of neuroleptic dosage over a decade
Authors: G T Reardon, A Rifkin, A Schwartz, A Myerson, S G Siris
Journal: American Journal of Psychiatry (1989)

A study of patterns of neuroleptic dosage for 206 schizophrenic inpatients showed significant differences over time and among three centers--a general hospital psychiatric unit, a community mental health center, and a state hospital. In 1982 patients' mean dose at discharge was higher than the peak mean daily dose in 1973, and high-potency neuroleptics were being used almost exclusively. The mean length of stay decreased from 49 days in 1973 to 34 days in 1982. The possible relationship, if any, between increasing dosage, decreased length of stay, and the switch from low-potency to high-potency neuroleptics remains undetermined.
Finding Signals for Plant Promoters
Authors: Weimou Zheng
Journal: Genomics Proteomics & Bioinformatics (2003)

Abstract The strongest signal of plant promoter is searched with the model of single motif with two types. It turns out that the dominant type is the TATA-box. The other type may be called TATA-less signal, and may be used in gene finders for promoter recognition. While the TATA signals are very close for the monocot and the dicot, their TATA-less signals are significantly different. A general and flexible multi-motif model is also proposed for promoter analysis based on dynamic programming. By extending the Gibbs sampler to the dynamic programming and introducing temperature, an efficient algorithm is developed for searching signals in plant promoters.
HG-53HYPERMUTATION AND NEOANTIGEN FORMATION PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN CHILDHOOD BIALLELIC MISMATCH REPAIR DEFICIENT GLIOBLASTOMA
Authors: Brittany Campbell, Eric Bouffet, Valerie Larouche, Gary Mason, Alyssa Reddy, Michael Osborn, Vanan Magimairan, Daniele Merico, Richard de Borja, Brian Chung, Melissa Galati, Melyssa Aronson, Carol Durno, Joerg Kruger, Vanja Cabric, Nataliya Zhukova, Vijay Ramaswamy, Roula Farah, Samina Afzal, Michal Yalon, Gideon Rechavi, Michael F. Walsh, Shlomi Constantini, Rina Dvir, Ronit Elhasid, Michael Sullivan, Jordan R. Hansford, Andrew Dodgshun, Nancy Klauber-Demore, Lindsay Peterson, Sunil Patel, Scott Lindhorst, Jeffrey Atkinson, Rachel Laframboise, Zane Cohen, Peter Dirks, Michael Taylor, David Malkin, Steffen Albrecht, Roy Dudley, Nada Jabado, Cynthia Hawkins, Adam Shlien, Uri Tabori
Journal: Neuro-Oncology (2016)
Soundings: Gifted and black?
Authors: Trisha Greenhalgh
Journal: BMJ (2006)

A Leeds university lecturer was dismissed last month for claiming that the intelligence quotient of black people is lower than that of white people. The Times Higher Education Supplement ran articles on the incident that defended both students' right to boycott lectures and freedom of speech in a democratic society. On the letters page, a black lecturer was given his protest slot, but others emphasised the sanctity of scientific evidence, however unpalatable.

One correspondent reminded readers that IQ is related to brain size, and that blacks were shown years ago to have smaller brains. The experiments to which he refers were done by a 19th century craniometrist, Samuel George Moreton, who filled a selection of skulls with mustard seed to estimate their volume. The “white” skulls had larger volumes. Moreton's experiments were later repeated by others, with the same skulls but three key methodological changes. Firstly, mustard seed (which is compressible) was replaced by lead shot. Secondly, data were controlled for gender, exposing Moreton's decision to compare female black skulls with male white ones. Thirdly, data were reanalysed by a researcher who was unaware of each skull's racial origin. The differences between the groups disappeared.

IQ tests were developed in the 1930s by US scientists to justify policies that many would now classify under the heading “eugenics”—especially selective immigration bans. Test items purporting to measure innate intellectual ability asked new migrants to label the parts of a buffalo (in English), identify sentences in ethnic dialects as grammatically “wrong,” and give the “correct” free text response to questions such as “Why should we not give to beggars?”

My children attend a selective state school whose entrance examination has been designed to exclude overt cultural and socio-economic biases. From a catchment area in which 80% of people classify themselves as white, 65% of the school's intake is from non-white groups—perhaps because many such families view academic achievement as a route to social mobility and set a higher work ethic than the white majority.

The real scandal is not that a lecturer has been dismissed for asserting that IQ differences are the cause rather than the effect of social inequalities, but that many academics appear to lack the skills to question the evidence.
One-Shot Intravesical Instillation of the Mucous Adhesive Anticancer Agent Hydroxypropylcellulose- Doxorubicin for the Treatment of Superficial Bladder Carcinoma Is Sufficient to Determine Antitumor Effects
Authors: Kousuke Ueda, Hiroshi Sakagami, Yasuhiko Masui, Takehiko Okamura, Kazuo Ohtaguro
Journal: European Urology (1993)
Lack of Impact of Electronic Health Records on Quality of Care and Outcomes for Ischemic Stroke
Authors: Karen E. Joynt, Deepak L. Bhatt, Lee H. Schwamm, Ying Xian, Paul A. Heidenreich, Gregg C. Fonarow, Eric E. Smith, Megan L. Neely, Maria V. Grau-Sepulveda, Adrian F. Hernandez
Journal: Journal of the American College of Cardiology (2015)
New perspectives in psychiatry in the Veterans Administration
Authors: J J Baker
Journal: American Journal of Psychiatry (1975)

In 1972, the mental health services in the Veterans Administration were reorganized in a manner designed to increase the probability of interdisciplinary collaboration. VA hospitals were urged to form multidisciplinary mental health committees to advise on local programs and practices. This "corporate" approach has led to significant changes in the use of staff and in the physical and psychological environment in some hospitals. While it is too early to evaluate the full impact of the changes on patient care, waiting lists have been reduced and length of hospital stay has decreased.
Corrigendum to “Metformin-associated lactic acidosis: Current perspectives on causes and risk” [Metabolism 65 (2016) 20–29]
Authors: Ralph DeFronzo, G. Alexander Fleming, Kim Chen, Thomas A. Bicsak
Journal: Metabolism (2016)

The authors regret that the x-axis data labels in Fig. 2 were incorrectly rendered in the original article. The corrected figure is reprinted here. The authors apologize for any inconvenience this may have caused. Metformin-associated lactic acidosis: Current perspectives on causes and riskMetabolism - Clinical and ExperimentalVol. 65Issue 2PreviewAlthough metformin has become a drug of choice for the treatment of type 2 diabetes mellitus, some patients may not receive it owing to the risk of lactic acidosis. Metformin, along with other drugs in the biguanide class, increases plasma lactate levels in a plasma concentration-dependent manner by inhibiting mitochondrial respiration predominantly in the liver. Elevated plasma metformin concentrations (as occur in individuals with renal impairment) and a secondary event or condition that further disrupts lactate production or clearance (e.g., cirrhosis, sepsis, or hypoperfusion), are typically necessary to cause metformin-associated lactic acidosis (MALA). Full-Text PDF Open Access
Case two. Bleomycin cutaneous toxicity.
Authors: W Yeo, P J Johnson
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.4.1626 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9552075 Case two. Bleomycin cutaneous toxicity. W YeoxW YeoSearch for articles by this author , P J JohnsonxP J JohnsonSearch for articles by this author Show More Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT. https://doi.org/10.1200/JCO.1998.16.4.1626 First Page PDF © 1998 by American Society of Clinical Oncology
Production of Prolonged Arterial Hypertension in Dogs by Chronic Stimulation of the Nervous System
Authors: ROBERT D. TAYLOR, IRVINE H. PAGE
Journal: Circulation (1951)

We were unable to produce chronic arterial hypertension in dogs by severe cerebral ischemia induced by ligation of blood supply to the brain. Combining cerebral ischemia with the mechanical effect of a wire in the floor of the fourth ventricle and the thermal stimulus of heat generated in this wire by short wave diathermy resulted in hypertension that lasted as long as 10 months. Experiments are described which indicate that the arterial hypertension which accompanies increased cerebrospinal fluid pressure is in part the result of pressure on the brain and not entirely due to cerebral anemia.
GC-09GENOME-WIDE DNA METHYLATION AND TRANSCRIPTOMIC PROFILING IN PRIMARY CENTRAL NERVOUS SYSTEM GERM CELL TUMORS SUGGESTS A PRIMORDIAL GERM CELL ORIGIN FOR GERMINOMA
Authors: Koichi Ichimura, Shintaro Fukushima, Satoshi Yamashita, Hisato Kobayashi, Hirokazu Takami, Yuko Matsushita, Sakura Kuzuoka, Hiromi Nakamura, Yasushi Totoki, Yoichi Nakazato, Tatsuhiro Shibata, Masao Matsutani, Toshikazu Ushijima, Ryo Nishikawa
Journal: Neuro-Oncology (2016)
Letter to the Editor
Authors: J. Brannath, U. Biewener
Journal: Endoscopy (1988)

See also: Non-surgical Endoscopic Trans-papillary Treatment of Ruptured Echinococcus Liver Cyst Obstructing the Biliary TreeEndoscopy 1987; 19(02): 81-83DOI: 10.1055/s-2007-1013021
A METHOD OF EVALUATING A THERAPEUTIC AGENT
Authors: ALBERT J. STUNKARD
Journal: American Journal of Psychiatry (1950)

1. A method of evaluating a therapeutic agent in psychiatric disorders is described. [see Tabel 1 in source pdf] 2. Advantages and disadvantages of such a method are discussed. 3. This method is used in a study of the effects of dibenamine in 30 patients suffering from various psychiatric disorders. 4. It is demonstrated that in the dosage used dibenamine is not more effective than a placebo in the care of patients as described. 5. Nausea and vomiting occurred in 11 of 30 patients receiving dibenamine, as against 2 receiving placebo. 6. An increase of symptoms was found in 3 of 5 depressed patients receiving dibenamine.
Targeting MTHFD2 in acute myeloid leukemia
Authors: Yana Pikman, Alexandre Puissant, Gabriela Alexe, Andrew Furman, Liying M. Chen, Stacey M. Frumm, Linda Ross, Nina Fenouille, Christopher F. Bassil, Caroline A. Lewis, Azucena Ramos, Joshua Gould, Richard M. Stone, Daniel J. DeAngelo, Ilene Galinsky, Clary B. Clish, Andrew L. Kung, Michael T. Hemann, Matthew G. Vander Heiden, Versha Banerji, Kimberly Stegmaier
Journal: The Journal of Experimental Medicine (2016)

Drugs targeting metabolism have formed the backbone of therapy for some cancers. We sought to identify new such targets in acute myeloid leukemia (AML). The one-carbon folate pathway, specifically methylenetetrahydrofolate dehydrogenase-cyclohydrolase 2 (MTHFD2), emerged as a top candidate in our analyses. MTHFD2 is the most differentially expressed metabolic enzyme in cancer versus normal cells. Knockdown of MTHFD2 in AML cells decreased growth, induced differentiation, and impaired colony formation in primary AML blasts. In human xenograft and MLL-AF9 mouse leukemia models, MTHFD2 suppression decreased leukemia burden and prolonged survival. Based upon primary patient AML data and functional genomic screening, we determined that FLT3-ITD is a biomarker of response to MTHFD2 suppression. Mechanistically, MYC regulates the expression of MTHFD2, and MTHFD2 knockdown suppresses the TCA cycle. This study supports the therapeutic targeting of MTHFD2 in AML.